NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DRNA shares have increased by 52.1% and is now trading at $25.67. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.28 by $0.59. The biopharmaceutical company had revenue of $34.03 million for the quarter, compared to analysts' expectations of $59.61 million. Dicerna Pharmaceuticals had a negative net margin of 213.04% and a negative return on equity of 74.79%. View Dicerna Pharmaceuticals' earnings history.

11 brokers have issued 1-year price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $34.20 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

Headlines about DRNA stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the next several days. View the latest news about Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a drop in short interest in June. As of June 15th, there was short interest totaling 3,210,000 shares, a drop of 5.0% from the May 31st total of 3,380,000 shares. Based on an average daily trading volume, of 669,800 shares, the short-interest ratio is presently 4.8 days. Currently, 5.0% of the company's shares are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Myokardia (MYOK), Blueprint Medicines (BPMC) and Nektar Therapeutics (NKTR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $25.67.

Dicerna Pharmaceuticals has a market capitalization of $1.90 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]